Waldencast's Obagi Medical Launches Two New Lip Therapy Products, AHA + PHA Smoothing Micro‑Peel And Soothe & Protect Lip Treatment SPF 30, As Targeted Treatment Protocol

Waldencast plc Class A -1.23%

Waldencast plc Class A

WALD

0.90

-1.23%

Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), continues its commitment to advanced skin science with the launch of two new lip innovations designed to work together as a targeted treatment protocol: Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30.

Building on the brand's legacy of clinically backed solutions for skin health and rejuvenation, the new Lip Therapy protocol brings Obagi's expertise to one of the most delicate areas of the face. Designed for nightly rejuvenation and daily protection, the two-step regimen gently resurfaces the lips while restoring hydration, improving texture, and defending against environmental stressors, including the sun's UV rays.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.